A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste is a research paper published in medRxiv (2022). On theSindex it has a DataRank of 1.4. It has been cited 27 times, with 27 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.500
From this paper's citation signal
Citation Network Contribution
0.868
From 26 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 27 citers.
National Institutes of Health
Grant: 5UL1RR024139-02
Clinical and Translational Science Award
NCRR NIH HHS
Grant: UL1 RR024139
NCATS NIH HHS
Grant: UL1 TR001863
Influential Citations
1
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals